The Boston Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.

Press releases published on April 29, 2026

Apr. 29, 2026

CPS Technologies Corp. Conference Call Notification

Indeterminate GlobeNewswire

Apr. 29, 2026

SOFI ALERT: Securities Fraud Investigation by Block & Leviton Could Allow SoFi Technologies Investors to Recover Losses

Indeterminate GlobeNewswire

Apr. 29, 2026

POET LAWSUIT: POET Technologies Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

Indeterminate GlobeNewswire

Apr. 29, 2026

Merlin, Inc. Announces $80 Million PIPE Investment to Accelerate Program Execution and Unlock New Growth Opportunities

Indeterminate GlobeNewswire

Apr. 29, 2026

NARTP Strategic Innovation Center and Digital Twin Consortium Collaborate to Test and Develop Multi-Agent AI Digital Twins Across Aviation

Indeterminate GlobeNewswire

Apr. 29, 2026

Penn State University Selects Flywire to Power Tuition Management Processes for 100,000+ Students

Indeterminate GlobeNewswire

Apr. 29, 2026

Stop & Shop Releases 2025 Impact Report

Indeterminate GlobeNewswire

Apr. 29, 2026

Liberty Defense Appoints Seasoned Capital Markets Executive Will Hamilton to its Board of Directors

Indeterminate GlobeNewswire

Apr. 29, 2026

Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy's Annual Meeting

Indeterminate GlobeNewswire

Apr. 29, 2026

Inaugural Laudio-ASHHRA Report Reveals How HR Leaders Can Strengthen Workforce Stability Through Frontline Leadership

Indeterminate GlobeNewswire

Apr. 29, 2026

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Indeterminate GlobeNewswire

Apr. 29, 2026

Anika Reports First Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Apr. 29, 2026

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

Indeterminate GlobeNewswire

Apr. 29, 2026

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

Indeterminate GlobeNewswire

Apr. 29, 2026

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Indeterminate GlobeNewswire

Apr. 29, 2026

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

Indeterminate GlobeNewswire

Apr. 29, 2026

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Indeterminate GlobeNewswire